The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Analysis of serum biomarkers and tumor genetic alterations from a phase II study of lenvatinib in patients with advanced BRAF wild-type melanoma.
Pallavi Sachdev
Employment or Leadership Position - Eisai
Omid Hamid
Consultant or Advisory Role - Eisai
Research Funding - Eisai
Kevin Kim
Consultant or Advisory Role - Eisai
Research Funding - Eisai
Axel Hauschild
Consultant or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; Oncoscience; Roche
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Research Funding - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; Oncoscience; Roche
Steven O'Day
Consultant or Advisory Role - Eisai
Research Funding - Eisai
Corina Andresen
Employment or Leadership Position - Eisai
Yasuhiro Funahashi
Employment or Leadership Position - Eisai
Stock Ownership - Eisai
Tadashi Kadowaki
Employment or Leadership Position - Eisai
Stock Ownership - Eisai
James P. O'Brien
Employment or Leadership Position - Eisai
Keith Flaherty
Consultant or Advisory Role - Eisai
Research Funding - Eisai